- "We plan to forge global 바카라 토토 사이트 partnerships with Korean and international biotech companies"
- "Committed to showcasing our advanced technology and growth potential at major Korean and international academic and industry conferences"
[by Lee, Young Sung] ENCell, an advanced biopharmaceutical CDMO and novel drug development company, announced on May 7 that it will participate in 'BIO KOREA 2025' with a promotional booth at COEX in Samseong-dong, Gangnam District, Seoul, from May 7 to 9, where the company will showcase its advanced biopharmaceutical CDMO capabilities and new drug pipeline.
At this year’s BIO KOREA event, 바카라 토토 사이트 plans to present in detail the growth potential and current status of its advanced biopharmaceutical CDMO business, which has gained recognition for its differentiated competitiveness by securing contracts from both Korean and international clients. Additionally, the company will promote its new drug pipeline, including EN001, which received orphan drug designation from the U.S. Food and Drug Administration (FDA) in February for the treatment of Charcot-Marie-Tooth disease.
In addition, 바카라 토토 사이트 intends to actively promote its capabilities at the event by pursuing business partnerships with local and international biotechnology companies, with a focus on securing global CDMO orders and exploring licensing opportunities. In particular, the company anticipates productive collaborations, as leading firms expressed interest in the company's differentiated CGT CDMO technology and GMP production capacity, which align with global quality standards.
"바카라 토토 사이트 aims to highlight its strengths as a leading Korean advanced biopharmaceutical CDMO and new drug development company at BIO KOREA 2025," an 바카라 토토 사이트 official said. "We plan to actively promote the company’s advanced technology and future growth potential at major domestic and international academic conferences in the future."